Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management
Disease overview: The myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN
Myelodysplastic Syndromes (MDS)
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse
Posttransplantation, glasdegib maintenance therapy in patients at high risk for relapse did not meaningfully reduce relapse incidence.Use of glasdegib in the posttransplantation setting was complicated by adverse events requiring drug holds and occasional discontinuation.
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)
The implementation of next-generation sequencing (NGS) has influenced diagnostic, prognostic, and therapeutic decisions in myeloid malignancies. However, the clinical relevance of serial molecular annotation in patients with myelodysplastic syndrome (MDS) undergoing active treatment is unknown.
HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML
Aberrant DNA methylation often silences transcription of tumor-suppressor genes and is considered a hallmark of myeloid neoplasms. Similarly, histone deacetylation represses transcription of genes responsible for cell differentiation/death. A previous clinical study suggested potential pharmacodynamic antagonism between histone deacetylase inhibitors (HDACi) and DNA hypomethylating agents (HMA).
Targeting the Microenvironment in MDS: The Final Frontier
Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone
Controversies on the Consequences of Iron Overload and Chelation in MDS
Many patients with MDS are prone to develop systemic and tissue iron overload iron overload: A condition that occurs when too much iron accumulates in the body.
Thomas G. DeLoughery, MD, MACP, FAWM
Institution
Oregon Health & Science University
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
About
Tom DeLoughery is a native Hoosier who graduated from Indiana State University in 1981 (one year after Larry Bird) and the Indiana University School of Medicine in 1985. He did his internship at the University of California, Irvine before traveling to Oregon where he finished his internal medicine residency and hematology/oncology fellowship. He is currently a professor of medicine, pathology and pediatrics in the Divisions of Hematology/Oncology and Laboratory Medicine at OHSU. His clinical interests are in blood diseases, hemostasis, and thrombosis, subjects on which he has written
Catherine Broome, MD
Institution
MedStar Health - Georgetown
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
About
Catherine M. Broome, MD, is board certified in internal medicine, hematology and medical oncology. She has been on staff at the MedStar Georgetown University Hospital's Lombardi Comprehensive Cancer Center for eight years. A fascination with the science of hematology and the opportunity to develop a strong relationship with patients and their families led Dr. Broome to specialize in hematology and medical oncology. Dr. Broome focuses on developing a partnership with her patients, providing them the most up-to-date information and treatment options. They work together to develop a treatment
Matt Kalaycio, MD
Institution
Cleveland Clinic Taussig Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
About
Matt Kalaycio, MD, FACP, is the former Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic Taussig Cancer Institute. Dr. Kalaycio is also a Professor in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Board-certified in hematology, Dr. Kalaycio's clinical interests are in leukemia and hematopoietic cell transplantation. Dr. Kalaycio has published over 200 articles in numerous scientific publications including Bone Marrow Transplantation, Journal of Clinical Oncology, and Leukemia. He serves on the editorial board of Biology of